⚠ Evidence note: Human outcome data on longevity interventions is limited; most claims rest on surrogate markers or animal models. Nothing here is medical advice.
Repurposable Drugs and Targets for Premature Ovarian Insufficiency
Current understanding
To be populated as evidence accumulates.
Evidence log
- 2026-10-03 — Elamipretide Rejuvenates Oocyte Quality and Restores Female Fertility During Reproductive Aging: cross-connection with elamipretide: Elamipretide becomes a candidate within the repurposable-drug landscape for ovarian aging and premature ovarian insufficiency. (novelty: 3)
- 2026-09-23 — Physical Activity Delays Ovarian Aging in Mice: cross-connection with adiponectin-receptor-agonists: Adiponectin receptor agonism emerges as a candidate mechanism for delaying ovarian aging, adding to the repurposable-target list for premature ovarian insufficiency. (novelty: 3)
- 2026-08-17 — Ovarian aging and systemic health: Mechanisms and emerging intervention strategies.: cross-connection with senolytics: Ovarian-aging review situates senolytics within the broader repurposable-drug landscape for premature ovarian insufficiency, adding senescent-cell clearance to the POI-target menu. (novelty: 3)
- 2026-08-28 — Identifying novel druggable targets and repurposable drugs for premature ovarian insufficiency by integrated multiomics and causal inference analysis.: Integrated multiomics MR pipeline surfaced seven causal POI proteins (EPHA4, FSTL3, NUCB2, OXT, SERPINA12, TNFRSF6B, FABP1); docking/MD nominated repurposable ligands including cycloheximide–EPHA4, framed as target-discovery leads rather than therapeutic evidence. [mechanism-plausible] (novelty: 3)
Open questions
Related
Contributing findings
Identifying novel druggable targets and repurposable drugs for premature ovarian insufficiency by integrated multiomics and causal inference analysis.
28-aug-2026
novelty 3
per-area 3
strengthens